Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

GlobeNewsWire • Feb 4, 2026

Tenax Therapeutics: A Speculative Buy

Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-HFpEF and a favorable risk/reward profile. Levosimendan's Phase III trial remains well powered, but the main end-point risk persists, with a realistic 60–70% chance of success. The risk-adjusted conservative revenue estimate for TENX's lead asset well supports the company's current $450M market cap with substantial upside optionality.

Seeking Alpha • Jan 9, 2026

Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing

Tenax Therapeutics (TENX) initiated with a Buy rating and a $25 price target, implying 127% upside based on DCF analysis. TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with a 65% PoS and strong Phase 2 efficacy signals. Valuation assumes $500M peak sales by 2035, conservative market penetration, and robust cash position minimizing near-term dilution risk.

Seeking Alpha • Jan 5, 2026

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD), the primary endpoint.

GlobeNewsWire • Dec 17, 2025

Tenax Therapeutics to Participate in Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:

GlobeNewsWire • Nov 25, 2025

Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript

Tenax Therapeutics, Inc. ( TENX ) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF November 13, 2025 4:30 PM EST Company Participants Christopher Giordano - CEO, President & Director Stuart Rich - Chief Medical Officer & Director Sanjiv Shah Barry Borlaug Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to the Tenax Therapeutics Virtual KOL Call.

Seeking Alpha • Nov 14, 2025

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026

GlobeNewsWire • Nov 12, 2025

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m.

GlobeNewsWire • Nov 6, 2025

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.

GlobeNewsWire • Nov 3, 2025

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimendan Doses, and its Use in Combination with Various Cardiovascular Drugs in PH-HFpEF CHAPEL HILL, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the European Patent Office (EPO) has notified Tenax of its Intention to Grant a patent that will provide intellectual property (IP) protection for TNX-103 (oral levosimendan), and other formulations of levosimendan, as well as its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

GlobeNewsWire • Sep 16, 2025